Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | PREP | P48147 | 2/20 | 0.30 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.30 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27950403 | 0.98 | GAA (0.41) | DGAT1GAAEPHX1CHRM3HPGD | |
| SCHEMBL27566889 | 0.92 | DGAT1 (0.40) | DGAT1GAAEPHX1CHRM3HPGD | |
| Hydrochloric Acid SCHEMBL6600019 | 0.90 | DGAT1 (0.39) | DGAT1GAAEPHX1CHRM3HPGD | |
| SCHEMBL26698284 | 0.85 | EPHX1 (0.38) | DGAT1GAAEPHX1CHRM3HPGD | |
| SCHEMBL26698295 | 0.84 | EPHX1 (0.40) | DGAT1GAAEPHX1HPGDHDAC4 | |
| SCHEMBL28857843 | 0.83 | EPHX1 (0.40) | DGAT1GAAEPHX1SSTR4PDK1 | |
| SCHEMBL6512299 | 0.82 | DGAT1 (0.41) | DGAT1GAAEPHX1CHRM3HPGD | |
| SCHEMBL23116644 | 0.82 | BTK (0.40) | DGAT1CHRM3HPGDCHRM2CHRM1 | |
| SCHEMBL28770712 | 0.82 | EPHX1 (0.43) | GAAEPHX1SSTR4PDK1PDK2 | |
| SCHEMBL7352590 | 0.82 | EPHX1 (0.43) | GAAEPHX1SSTR4PDK1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072802-A1 | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | DUAN JINGWU (US) | 2004-04-15 | — | — | US | disclosed |
| EP-1263756-B1 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-02-25 | — | — | EP | disclosed |
| CN-1420881-A | Beta-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-alpha | BRISTOL MYERS SQUIBB PHARMACEU (US) | 2003-05-28 | — | — | CN | disclosed |
| US-6495565-B2 | FOR THERAPY OF ACUTE INFECTION, ACUTE PHASE RESPONSE, AGE RELATED MACULAR DEGENERATION, ALCOHOLISM, ANOREXIA, ASTHMA, AUTOIMMUNE DISEASE, AUTOIMMUNE HEPATITIS, BECHET'S DISEASE, CACHEXIA, CALCIUM PYROPHOSPHATE DIHYDRTATE DEPOSITION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-17 | — | — | US | disclosed |
| EP-1263756-A2 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | Bristol-Myers Squibb Pharma Company (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020013341-A1 | Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-31 | — | — | US | disclosed |
| WO-2001070734-A2 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072802-A1 | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | TNF, XPNPEP1, MMP2 | DGAT1 4230/4885GAA 272/4885EPHX1 728/4885 |
| US-20020013341-A1 | Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha | TNF, XPNPEP1, MMP2 | DGAT1 4335/4885GAA 280/4885EPHX1 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.